622.95
+1.05
+(0.17%)
At close: 3:29:48 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
5,220,289
4,734,179
6,457,961
6,798,898
6,557,828
Cost of Revenue
2,805,305
2,591,272
3,868,834
4,960,529
4,629,256
Gross Profit
2,414,984
2,142,907
2,589,127
1,838,369
1,928,572
Operating Expense
1,824,131
1,655,770
1,646,057
797,304
716,423
Operating Income
590,853
487,137
943,070
1,041,065
1,212,149
Net Non Operating Interest Income Expense
-275,782
-294,187
-172,506
-126,104
-81,705
Pretax Income
-8,635
-166,755
781,821
896,846
1,188,197
Tax Provision
-1,988
-23,489
146,497
182,987
357,107
Net Income Common Stockholders
-16,066
-837,931
430,244
713,859
831,089
Diluted NI Available to Com Stockholders
-16,066
-837,931
430,244
713,859
831,089
Basic EPS
-1.11
-30.36
15.59
25.87
30.11
Diluted EPS
-1.12
-30.36
15.59
25.87
30.11
Basic Average Shares
28,728.48
27,598.40
27,598.40
27,598.40
27,598.40
Diluted Average Shares
28,750.94
27,598.40
27,598.40
27,598.40
27,598.40
Rent Expense Supplemental
--
11,808
14,556
12,286
12,538
Total Expenses
4,629,436
4,247,042
5,514,891
5,757,833
5,345,679
Net Income from Continuing & Discontinued Operation
-16,066
-837,931
430,244
713,859
831,089
Normalized Income
285,625.48
182,937.68
628,734.65
714,771.97
831,111.38
Interest Income
--
3,287
4,281
1,717
1,669
Interest Expense
272,129
290,534
163,990
110,014
83,374
Net Interest Income
-275,782
-294,187
-172,506
-126,104
-81,705
EBIT
263,494
123,779
945,811
1,006,860
1,271,571
EBITDA
540,340
438,252
1,219,365
1,183,226
1,432,813
Reconciled Cost of Revenue
2,805,305
2,591,272
3,868,834
4,960,529
4,629,256
Reconciled Depreciation
276,846
314,473
273,554
176,366
161,242
Net Income from Continuing Operation Net Minority Interest
-6,647
-143,266
635,325
713,859
831,089
Total Unusual Items Excluding Goodwill
-379,686
-379,686
8,110
-1,147
-32
Total Unusual Items
-379,686
-379,686
8,110
-1,147
-32
Normalized EBITDA
920,026
817,938
1,211,255
1,184,373
1,432,845
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-87,413.52
-53,482.32
1,519.65
-234.03
-9.62
3/31/2021 - 5/10/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PARMAX.BO Parmax Pharma Limited
43.00
-0.58%
ANUHPHR.BO Anuh Pharma Limited
173.70
-0.23%
AARTIPHARM.BO Aarti Pharmalabs Limited
717.20
+0.68%
HIKAL.BO Hikal Limited
433.05
+4.50%
GLENMARK.BO Glenmark Pharmaceuticals Limited
1,356.95
-1.34%
LUPIN.BO Lupin Limited
1,935.80
-3.79%
GLAND.BO Gland Pharma Limited
1,443.25
+1.17%
NEULANDLAB.BO Neuland Laboratories Limited
12,742.10
+0.69%
SUVEN.NS Suven Life Sciences Limited
126.14
-1.12%
SOLARA.NS Solara Active Pharma Sciences Limited
519.25
+0.25%